Clinical Trials Browser

Unknown × INDUSTRY × Non-Muscle Invasive Bladder Neoplasms × Clear all

Non-Muscle Invasive Bladder Neoplasms

NCT05508568 2023-02-01

A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer

Unknown

650 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT04819399 2022-04-05

Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC

Phase 1 Unknown

30 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT04490993 2022-02-22

ACCRUE

Phase 3 Unknown

359 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT04736394 2022-02-22

ASCERTAIN

Phase 3 Unknown

800 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT04859751 2021-04-26

Study of VB4-845 Injection for Treating Patients With Non-muscle Invasive Bladder Cancer

Phase 3 Unknown

53 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT03560479 2020-08-19

A First-in-Human Study of alpha1H in Patients With Non-muscle Invasive Bladder Cancer

Phase 1/2 Unknown

52 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Neoplasms

NCT00109655 2008-10-03

Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure

Phase 1 Unknown

75 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Adenoviridae Infections, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

Clinical Trials

EVALUATION

A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer

Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC

ACCRUE

ASCERTAIN

Study of VB4-845 Injection for Treating Patients With Non-muscle Invasive Bladder Cancer

A First-in-Human Study of alpha1H in Patients With Non-muscle Invasive Bladder Cancer

Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure